Prothena | PRTA - Cash And Equivalent


Prothena reported $330.84M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 166.44M 29.14M Sep/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Immunic USD 35.13M 20.18M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Prothena USD 330.84M 40.6M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024